SCHEDULE 13G/A: Tang Capital Group Discloses 8.0% Passive Stake in Compass Therapeutics
Beneficial Ownership Report
Tang Capital Management and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.0% in Compass Therapeutics, Inc., totaling 11,052,632 shares.
Summary
- Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc., collectively reported beneficial ownership of 11,052,632 shares of Compass Therapeutics, Inc. Common Stock.
- This aggregate ownership represents 8.0% of the Issuer's outstanding Common Stock.
- The percentage is based on 138,282,498 shares of Common Stock outstanding as of February 15, 2025, as reported in Compass Therapeutics' Annual Report on Form 10-K filed on February 27, 2025.
- All reported shares are held with shared voting and shared dispositive power among the Tang Capital entities and Kevin Tang.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in beneficial ownership from a previous filing, and certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a passive beneficial ownership stake by an investment group, indicating continued interest in the company without suggesting any immediate strategic changes or financial performance implications.
Positives
- Tang Capital Management and its affiliates maintain a significant 8.0% stake in Compass Therapeutics, indicating continued investment interest from a notable investment group.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by an investment group, which may influence market perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-02-15 | Date as of which 138,282,498 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-K. |
| 2025-02-27 | Date the Issuer's Annual Report on Form 10-K was filed with the SEC. |
| 2025-03-31 | Date of event which requires filing of this statement. |
| 2025-05-15 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Compass Therapeutics, Tang Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.